Background and Aims: It is known that SGLT-2 inhibitors and GLP-1 agonists show a favorable profile in the reduction of body weight as well as blood pressure (BP). Therefore, the purpose of this study is to evaluate the effect of SGLT-2 inhibitors and GLP-1 agonists on ambulatory BP in patients with poorly controlled type 2 diabetes (T2D).

Materials and Methods: A total of 74 patients with T2D: 42 on GLP-1 agonists (group Α) [20 men, mean age (±standard deviation) 60.6±9.4 years, HbA1c 8.5±1,1%, body mass index (BMI) 37.1±5.3 Kg/m2, T2D duration 10.1±4.3] and 32 on SGLT-2 inhibitors (group Β) [16 men, mean age 64.8±7.1 years, HbA1c 8.2±1.3%, BMI 32,1±9,2 Kg/m2]. All patients underwent a complete clinical and laboratory examination. Ambulatory BP recording at baseline and three months after initiation of treatment with the oscillometric Mobil-O-Graph NGW 24-hour ambulatory BP and PWA monitor (IEM; Stolberg, Germany).

Results: At baseline, mean daytime systolic and diastolic BP in group A were: 128.0±11.2 and 77.2±11.0 mmHg and in group B: 129.6±14.8 and 78.1±9.9 mmHg, respectively (P=0.78 and P=0.81, respectively, for the comparison between the study groups). Regarding the nighttime recordings of BP in group A, mean systolic and diastolic BP were: 127.5±12.6 and 73.7±14.2 mmHg. In group B, mean systolic and diastolic BP were: 126.3±12.5 and 74.1±8.7 mmHg (P=0.57 and P=0.67, respectively, for the comparison between the study groups). After 3-month therapy, mean systolic BP (group A versus B) was 124.0±7.8 versus 128.2±10.4 mmHg (P=0.04) and mean diastolic BP, 73.5±7.8 versus 78.3±7.8 mmHg (P=0.05). Regarding nighttime systolic BP was 118.6±11.1 (group Α) versus 117.4±9.3 mmHg (group Β) (P=0.54) and for mean diastolic BP 68.1±9.8 (group Α) versus 69.6±7.1 mmHg (group Β) (P=0.69).

Conclusion: Three-month therapy with GLP-1 agonists had a favorable effect of ambulatory systolic and diastolic BP compared to SGLT-2 inhibitors.

Disclosure

A. Papazafiropoulou: None. S. S. Papantoniou: None. M. Rallatou: None. A. J. Melidonis: None. S. Antonopoulos: None.

© 2021 by the American Diabetes Association
2021
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.